Cytomegalovirus retinitis in a patient with systemic lupus erythematosus.
|
Accession number;99A0239366
|
| Title;Cytomegalovirus retinitis in a patient with systemic lupus erythematosus. |
| Author;
KAMBARA CHIHO
(Jichi Med. Sch.)
SHIBUI HIROBUMI
(Jichi Med. Sch.)
KAWASHIMA HIDETOSHI
(Jichi Med. Sch.)
|
Journal Title;Ophthalmology
|
Journal Code:Z0277A
|
ISSN:0016-4488
|
|
VOL.41;NO.1;PAGE.107-112(1999)
|
| Figure&Table&Reference;FIG.3, TBL.1, REF.16 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We report here on a patient with systemic lupus erythematosus(SLE) who developed cytomegalovirus(CMV) retinitis. A 37-year-old female, whose SLE was diagnosed at the age of 15, had been systematically treated with corticosteroid and cyclophosphamide for an extended period of time. On December 13, 1996, when her fundus were routinely checked, retinal exudates in her right eye were detected for the first time. She was treated as having developed SLE retinopathy, which progressively worsened. Following a series of laboratory tests, the presence of CMV antigenemia and her immunosuppressed status(CD4+ cell count 81/mm3) eventually lead us to the diagnosis of CMV retinitis. Systemic antiviral treatment with ganciclovir was immediately initiated on May 30 1997, and was effective for the first few months. The adverse side effect of bone marrow suppression compelled us to convert to intravitreous ganciclovir injection. During the next 9 months of the treatment, she received 25 injections to control this retinitis. The retinitis is currently under control and there have been no serious side effects. However, since she does not appear to be able to fully recover from an immunosuppressed condition, she will need to receive the injection for the remainder of her life. Thus, it is our pressing hope that long term-therapy of CMV retinitis becomes available for non-AIDS patients in the near future. (author abst.) |
|
|
|
Related Articles;
|
|
